🇺🇸 FDA
Patent

US 7405233

Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease

granted A61KA61K31/17A61K31/4166

Quick answer

US patent 7405233 (Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease) held by PTC THERAPEUTICS, INC. expires Mon Jul 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jul 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/17, A61K31/4166, A61K31/4172, A61K31/4196